28 Aug 2016 Jahr - FDA announced required class-wide changes to drug labeling to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system depressant drugs called benzodiazepines. Among the changes, the FDA is requiring boxed warnings and Medication Guides.
Zugefügt zum Band der Zeit:
Datum:
28 Aug 2016 Jahr
Jetzt
~ 9 years ago